ÂÜÀòÂÒÂ×

Joel Rubenstein is a seasoned executive with extensive experience in the healthcare and consumer goods sectors, currently serving as the Global VP and Category Head for Nicotine Replacement Therapy at Vectura Fertin Pharma since April 2023. Previously, Joel held the position of President at Niconovum AB, where leadership resulted in significant business growth and profitability. Joel's earlier roles include Global Marketing Director at GSK, Vice President at The Nielsen Company, and various marketing positions at Pfizer Consumer Healthcare. Joel has a strong educational background, holding an MBA from London Business School, a Bachelor's Degree in Economics from Columbia University, and a Master's Degree in Finance from New York University.